Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Not Confirmed
Not Confirmed
12-14 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Not Confirmed
12-14 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
05 Nov 2024
// INDPHARMAPOST
https://www.indianpharmapost.com/news/lonzas-synaffix-collaborates-with-bighat-biosciences-for-ml-designed-adc-16386
04 Nov 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/bighat-unveils-next-gen-adc-designed-lonzas-synaffix-1st-program-slated-clinical-trials
06 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-biologics-and-synaffix-expand-adc-collaboration-following-positive-preliminary-clinical-signal-from-ongoing-phase-1-study-302008005.html
17 Oct 2023
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/synaffix-signs-740m-deal-european-biotech-access-adc-tech-solid-tumor-strategy
12 Oct 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/synaffix-to-launch-new-adc-technologies-at-the-world-adc-conference-in-san-diego-301953968.html
01 Jun 2023
// CONTRACT PHARMA
https://www.contractpharma.com/contents/view_breaking-news/2023-06-01/lonza-acquires-synaffix-for-100m/?widget=listSection
Details:
Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates, including IBI343, a recombinant human anti-Claudin 18.2 monoclonal antibody-drug conjugate.
Lead Product(s): IBI-343
Therapeutic Area: Oncology Brand Name: IBI-343
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 06, 2023
Lead Product(s) : IBI-343
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates, including IBI343, a recombinant human anti-Claudin 18.2 monoclonal antibody-drug conjugate.
Brand Name : IBI-343
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 06, 2023
Details:
Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Large molecule
Sponsor: Sotio
Deal Size: $740.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Sotio
Deal Size : $740.0 million
Deal Type : Licensing Agreement
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
Details : Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 16, 2023
Details:
Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Sponsor: ABL Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2023
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products
Details : Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 13, 2023
Details:
Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Sponsor: MacroGenics
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : MacroGenics
Deal Size : $2,200.0 million
Deal Type : Licensing Agreement
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Details : Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-cla...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 14, 2023
Details:
Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Sponsor: Chong Kun Dang Pharm
Deal Size: $132.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 06, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Chong Kun Dang Pharm
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 06, 2023
Details:
Amgen will gain access to Synaffix's antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads for one Antibody Drug Conjugate (ADC) program.
Lead Product(s): Antibody-drug Conjugate-based Therapy
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Large molecule
Sponsor: Amgen Inc
Deal Size: $2,000.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2023
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Amgen Inc
Deal Size : $2,000.0 million
Deal Type : Licensing Agreement
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
Details : Amgen will gain access to Synaffix's antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads for one Antibody Drug Conjugate (ADC) program.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 05, 2023
Details:
Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Lead Product(s): Antibody-drug Conjugate-based Therapy
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Hummingbird Bioscience
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2023
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Hummingbird Bioscience
Deal Size : $150.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 04, 2023
Details:
Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Emergence Therapeutics
Deal Size: Undisclosed Upfront Cash: $360.0 million
Deal Type: Licensing Agreement September 06, 2022
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Emergence Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal
Details : Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $360.0 million
September 06, 2022
Details:
The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.
Lead Product(s): Antibody-drug Conjugate Therapeutic
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Kyowa Kirin
Deal Size: $176.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement June 30, 2022
Lead Product(s) : Antibody-drug Conjugate Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Kyowa Kirin
Deal Size : $176.0 million
Deal Type : Licensing Agreement
Details : The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $5.0 million
June 30, 2022
Details:
Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads for the discovery of Antibody-drug Conjugate.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Large molecule
Sponsor: MacroGenics
Deal Size: $586.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 03, 2022
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : MacroGenics
Deal Size : $586.0 million
Deal Type : Agreement
Synaffix Inks $586m Deal with MacroGenics to Enable Next Generation ADCs
Details : Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads for the discovery of Antibody-d...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 03, 2022
ABOUT THIS PAGE
Synaffix is a supplier offers 3 products (APIs, Excipients or Intermediates).
Find a price of UDP-AZIDOSUGAR bulk with DMF offered by Synaffix
Find a price of ENDOGLYCOSIDASE SH (ENDOSH) bulk with DMF offered by Synaffix
Find a price of GLYCOSYLTRANSFERASE (GT) bulk with DMF offered by Synaffix
LOOKING FOR A SUPPLIER?